SOURCE: Marathon Patent Group

June 15, 2015 08:15 ET

Marathon Patent Group Receives Order Setting Case Schedule in Signal IP and Updates Key Court Dates

LOS ANGELES, CA--(Marketwired - Jun 15, 2015) - Marathon Patent Group, Inc. (NASDAQ: MARA) ("Marathon"), a patent licensing company, announced that on June 12, 2015, the company's subsidiary Signal IP, Inc., received an order setting the trial schedule in the matter of Signal IP, Inc. v. Nissan North America, Inc., case number CV14-02962 JAK (C.D. Cal.).

The order also applies to the Cases of: "Signal IP, Inc. v. Mazda Motor of America, Inc.," "Signal IP, Inc. v. Mitsubishi Motors of North America, Inc.," "Signal IP, Inc. v. American Honda Motor Co., Inc.," "Signal IP, Inc. v. Kia Motors America, Inc.," "Signal IP, Inc. v. Subaru of America, Inc.," "Signal IP, Inc. v. Mercedes-Benz USA, LLC et al.," "Signal IP, Inc. v. BMW of North America, LLC et al.," "Signal IP, Inc. v. Volkswagen Group of America, Inc.," and "Signal IP, Inc. v. Porsche Cars of North America, Inc."

On May 26, 2015, The District Court of The Central District of California ("the Court") issued an order denying the motion to stay pending reexamination submitted by defendants Volkswagen Group of America, Inc. and Bentley Motors, Inc. In its conclusion, the Court ruled, "For the foregoing reasons, when all the relevant factors are considered, there is not a sufficient basis to enter the requested stay. Therefore, the motion is DENIED."

On June 12, 2015, the Company's subsidiary, Signal IP, Inc., received an order setting the trial schedule as follows:

Trial 1: March 15, 2016 at 9:00 am

Trial 2: May 10, 2016 at 9:00 am

Trial 3: July 12, 2016 at 9:00 am

Trial 4: September 13, 2016 at 9:00 am

Subsequent trials shall start approximately every 60 days thereafter. If an action against one defendant is resolved, then all subsequent actions are moved up to an earlier date.

Doug Croxall, CEO of Marathon stated, "We are pleased both by the Courts ruling denying the defendants requested stay, followed by its order setting the trial schedule. With the first trial commencing March 15, 2016, followed by one every 60 days thereafter, and defendants subject to being advanced on the calendar if an action against one defendant is resolved, we are ensured an accelerated trial schedule. With discovery now open, and having already reached settlements with previous defendants, we hope that the trial schedule will foster additional settlement activity and revenue generation. The addition of these trials only adds to an already expansive list of potential revenue opportunities for the company."

Croxall continued, "In upcoming months, we expect to further leverage existing and already licensed assets in Signal and other portfolios owned by Marathon against entirely new defendants, building on the current approximate 50 defendant count. We believe there remains significant opportunity within our current asset base to broaden the depth of monetization of existing revenue generating portfolios, as well as asserting assets currently not in monetization."

In addition to the trial scheduling order described above, the Company has also updated its current scheduled court calendar.

  • June 18 and 19, 2015 - An oral hearing is scheduled to begin in MedTech GmbH v. Stryker GmbH in the Munich District Court

  • June 29, 2015 - A Markman hearing is scheduled to be held in Selene v. Fluke Electronics Corporation in The U.S. District Court for the District of Delaware 

  • July 1, 2015 - An oral hearing is scheduled to begin in MedTech GmbH v. Joline GmbH in the Munich District Court

  • July 1, 2015 - An oral hearing is scheduled to begin in MedTech GmbH v. Maxxspine Ltd. in the Munich District Court

  • July 1, 2015 - An oral hearing is scheduled to begin in MedTech GmbH v. SAM in the Munich District Court

  • July 1, 2015 - An oral hearing is scheduled to begin in MedTech GmbH v. Signus Medizintechnik GmbH in the Munich District Court

  • July 21, 2015 - An oral hearing is scheduled to begin in MedTech GmbH v. Stryker GmbH in the Munich District Court

  • July 30, 2015 - An oral hearing is scheduled to begin in TLI Communications GmbH v. Facebook, Inc in the Munich District Court

  • July 30, 2015 - An oral hearing is scheduled to begin in TLI Communications GmbH v. Yahoo!, Inc in the Munich District Court

  • September 4, 2015 - A Markman hearing is scheduled in TLIF v. Biomet Inc. in The United States District Court for the Eastern District of Texas

  • September 14, 2015 - A jury trial is scheduled in IP Liquidity v. TRW in The U.S. District Court for the District of Delaware

  • September 17, 2015 - An oral hearing is scheduled to begin in TLI Communications GmbH v. Google, Inc in the Munich District Court

  • September 17, 2015 - An oral hearing is scheduled to begin in TLI Communications GmbH v. Apple in the Munich District Court

  • October 29, 2015 - An oral hearing is scheduled to begin in MedTech GmbH v. Stryker GmbH in the Munich District Court (Patents EP1104260 B2 and EP1938765 B1)

  • November 9, 2015 - A jury trial in E2E v. Cabelas, Inc. in The United States District Court for the Eastern District of Texas

  • December 1, 2015 - A Markman hearing is scheduled in Selene v. Trend Micro America, Inc. in The United States District Court, Northern District of California

  • December 3, 2015 - A Markman hearing is scheduled in Orthophoenix v. Osseon in The U.S. District Court for the District of Delaware

  • December 3, 2015 - A Markman hearing is scheduled in Orthophoenix v. Stryker Corporation in The U.S. District Court for the District of Delaware

  • December 3, 2015 - A Markman hearing is scheduled in Orthophoenix v. Dfine Inc. in The U.S. District Court for the District of Delaware

  • December 3, 2015 - A Markman hearing is scheduled in Orthophoenix v. Wright Medical Technology Inc. in The U.S. District Court for the District of Delaware

  • March 15, 2016 - A jury trial is scheduled in Signal v. (1 of 10 defendants) in the United States District Court for the Central District of California. *(Subsequent trials shall start approximately every 60 days thereafter. If an action against one defendant is resolved, then all subsequent actions are moved up to an earlier date)

  • April 11, 2016 - A jury trial is scheduled in TLIF v. Biomet Inc. in The United States District Court for the Eastern District of Texas

  • May 10, 2015 - A jury trial is scheduled in Signal v. 1 of 10 named defendants in the United States District Court for the Central District of California

  • June 16, 2016 - A jury trial is scheduled in IP Liquidity v. Celgene in The U.S. District Court for the District of Delaware

  • July 22, 2015 - A jury trial is scheduled in Signal v. 1 of 10 named defendants in the United States District Court for the Central District of California

  • August 8, 2016 - A jury trial is scheduled in Selene v. Fluke Electronics Corporation in The U.S. District Court for the District of Delaware

  • September 13, 2016 - A jury trial is scheduled in Signal v. 1 of 10 named defendants in the United States District Court for the Central District of California

  • November 15, 2016 (Approx) - A jury trial is scheduled in Signal v. 1 of 10 named defendants in the United States District Court for the Central District of California

  • January 15, 2017 (Approx) - A jury trial is scheduled in Signal v. 1 of 10 named defendants in the United States District Court for the Central District of California

  • March 15, 2017 (Approx) - A jury trial is scheduled in Signal v. 1 of 10 named defendants in the United States District Court for the Central District of California

  • May 15, 2017 (Approx) - A jury trial is scheduled in Signal v. 1 of 10 named defendants in the United States District Court for the Central District of California

  • June 12, 2017 - A jury trial is scheduled in Orthophoenix v. Osseon in The U.S. District Court for the District of Delaware

  • June 12, 2017 - A jury trial is scheduled in Orthophoenix v. v. Stryker in The U.S. District Court for the District of Delaware

  • June 12, 2017 - A jury trial is scheduled in Orthophoenix v. Dfine in The U.S. District Court for the District of Delaware

  • June 12, 2017 - A jury trial is scheduled in Orthophoenix v. Wright Medical in The U.S. District Court for the District of Delaware

  • July 15, 2017 (Approx) - A jury trial is scheduled in Signal v. 1 of 10 named defendants in the United States District Court for the Central District of California

  • September 15, 2017 (Approx) A jury trial is scheduled in Signal v. 1 of 10 named defendants in the United States District Court for the Central District of California

About Marathon Patent Group
Marathon is a patent acquisition and monetization company. The Company acquires patents from a wide-range of patent holders from individual inventors to Fortune 500 companies. Marathon's strategy of acquiring patents that cover a wide-range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long-term, diversified revenue stream. To learn more about Marathon Patent Group, visit www.marathonpg.com.

Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Information